Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naive Subjects With Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PERSPECTIVE
- Sponsors Pharmacyclics
- 28 Apr 2023 Planned End Date changed from 1 Jun 2026 to 25 Jun 2026.
- 28 Apr 2023 Planned primary completion date changed from 1 Jun 2026 to 25 Jun 2026.
- 20 Jul 2021 Planned End Date changed from 1 Jan 2025 to 1 Jun 2026.